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PreviewsIn their study Perry et al. (2014) judi-
ciously summoned up an assembly of
highly informative and complementary
methods, which allowed them to clear
up some smoldering and contentious
issues surrounding thymic tolerance in-
duction. At the same time they made
important and surprising observations.
The generous sharing by mTECs of their
most precious asset, the promiscuously
expressed self-antigen pool, with their
DC neighbors and its essential role
in shaping the Treg cell repertoire, is
perhaps the most intriguing and provoca-
tive discovery. Finding out the raison
d’eˆtre and the cellular and molecular un-
derpinning of this remarkable cellularcooperation should prove both chal-
lenging and rewarding.REFERENCES
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Transforming growth factor b (TGF-b) is a canonical immunosuppressive cytokine secreted by tumors. In this
issue of Immunity, Stephen et al. (2014) reveal that tumor-derived TGF-b deactivates antitumor CD8+ T cell
responses through T cell upregulation of the FoxP1 transcription factor.Transforming growth factor b (TGF-b) is
well known for favoring tissue invasion
and metastasis. Within tumors, it can be
produced by multiple cell types including
cancer cells themselves, dendritic cells
(DCs), regulatory T (Treg) cells, and con-
ventional T lymphocytes. TGF-b inhibits
innate immunity through several mecha-
nisms. Under the influence of TGF-b, neu-
trophils and macrophages convert from
the N1 and M1 to the N2 and M2 pheno-
types, respectively, becoming less cyto-
toxic and downregulating NF-kB activity.
DCs exposed to TGF-b acquire a tolero-
genic phenotype, contributing to Tregcell expansion. TGF-b also downregu-
lates NKp30 and NKG2D-dependent
effector functions, thereby reducing the
capacity of NK cells to secrete inter-
feron-g (IFN-g) and to kill target cells.
TGF-b also affects the adaptive arm of
anticancer immunity, by influencing the
survival, differentiation, proliferation, and
apoptosis of most T cell subsets. Indeed,
TGF-b promotes the differentiation of
inducible Treg cells and the maintenance
of natural Treg cells. TGF-b inhibits inter-
feron-g (IFN-g) and T-bet expression by
T helper 1 (Th1) cells and induces a shift
toward a Th2 or Th17 differentiation state.Finally, short-lived effector T cells residing
in tumor beds are particularly susceptible
to TGF-b-induced apoptosis (Flavell et al.,
2010).
In spite of this wealth of information, the
precise molecular mechanisms account-
ing for the immunosuppressive effects of
TGF-b signaling in growing tumors have
remained elusive apart from the fact
that, downstream of TGF-b receptor
signaling, the transcription factor Smad3
participates in interleukin-2 (IL-2)-depen-
dent and independent T cell repression
(McKarns et al., 2004). In this issue of
Immunity, Stephen et al. (2014) identifiedptember 18, 2014 ª2014 Elsevier Inc. 345
Figure 1. Tumor-Associated Immunosuppressive TGF-b-Foxp1
Axis
TGF-b (in coordination with Cxcl12) is secreted from the tumor mass. These
factors bind to their respective receptors on CD8+ T cells. This results in
FoxP1 transcription factor association with Smad2 and Smad3 with subse-
quent translocation to the nucleus. The FoxP1-Smad2-Smad3 complex re-
presses transcription of c-Jun and c-Myc. Consequently the T cell pool size
cannot expand and the tumor mass grows. FoxP1 also effects expression
of IFN-g and Granzyme B (Gzmb) in CD8+ T cells.
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PreviewsFoxp1 as a TGF-b-elicited
T cell-intrinsic transcription
factor that is capable of
switching off the AP1-depen-
dent T cell activation pro-
gram. Activation of TGF-b
receptors on tumor residing
CD8+ T cells that are en-
gaging in the MHC class
I-dependent recognition of tu-
mor cell antigens resulted in
the upregulation of the nu-
clear expression of Foxp1.
Within the nuclei of CD8+
T cells, Foxp1 physically in-
teracted with the newly trans-
located Smad2 and Smad3
proteins, leading to the
blockade of proliferation and
major T cell functions in-
cluding the degranulation of
cytotoxic granules and cyto-
kine release. Adoptively
transferred tumor-reactive
Foxp1/ T cells (or T cells ex-
pressing an inhibitory mutant
of the TGF-b receptor) were
able to control the outgrowth
of aggressive tumors without
apparent toxicity. This effect
could be phenocopied by the
concomitant neutralization of
the chemokine Cxcl12 in
combination with TGF-b, amanipulation that stimulated the anti-
cancer activity of intratumoral T lympho-
cytes (Figure 1). Transcriptional repres-
sion of c-Jun (and not NFAT), which is
one of the proteins composing the AP1
complex, was necessary and sufficient
tomediate Foxp1-induced T cell inhibition
in as much as enforced expression of c-
Jun could restore the T cell receptor
(TCR)-driven proliferative capacity of
CD8+ T cells in vitro (Stephen et al., 2014).
The question then comes up as to
whether Foxp1 might be involved in
T cell anergy (Schwartz, 2003), exhaus-
tion (Barber et al., 2006), or senescence
(Akbar andHenson, 2011). This is a partic-
ularly relevant query as uncontrolled
oncogenic processes invariably offer an
orchestrated microenvironment where
anergy, exhaustion, and senescence ac-
count for T cell dysfunctions and tumor
escape (Zitvogel et al., 2006, Pardoll,
2012). Foxp1 is not only overexpressed
in CD8+ T cells infiltrating mouse tumors.
Rather, its human ortholog, FOXP1, is346 Immunity 41, September 18, 2014 ª2014also highly expressed by T cells infiltrating
several cancer types including ovarian
and breast carcinomas. The upregulation
of Foxp1 transcription is observed in
PD1 (more so than in PD1+) tumor-infil-
trating lymphocytes, regardless of their
activation status, as judged from the
expression of CD44, CD45RA, or CD69
(Doering et al., 2012; Stephen et al.,
2014). To address the role of Foxp1 in
controlling immunosurveillance, Stephen
et al. (2014) generated tumor-reactive
CD8+ T cells by priming splenic naive
T cells with syngeneic DCs pulsed with
irradiated ovarian tumor cells for 7 days
(Stephen et al., 2014). In these ex vivo cul-
ture assays, T cells failed to express rele-
vant Foxp1 isoforms (Foxp1a and
Foxp1d). However, 48 hr after adoptive
transfer into cancer-bearing mice, T cells
that accumulated in tumor beds over-
expressed Foxp1, indicating that origi-
nally Foxp1 cells can acquire Foxp1
expression in themalignant microenviron-
ment. Only Foxp1-deficient T cells (fromElsevier Inc.Cd4-cre;Foxp1fl/fl mice) were
able to proliferate within tu-
mor beds, to secrete IFN-g
and to synthesize Granzyme
B, eventually leading to tumor
regression. Therefore, rather
than reflecting a known type
of T cell dysfunction, Foxp1
appears as a hallmark of
‘‘unresponsiveness’’ affecting
CD8+ T lymphocytes (Ste-
phen et al., 2014).
The function of Foxp1 has
previously been studied in
mature CD8+ T cells through
the use of an inducible dele-
tion model system. Loss of
Foxp1 triggers IL-7-depen-
dent T cell proliferation with
enhanced effector functions
(Feng et al., 2011). By nega-
tively regulating IL-7Ra
expression (more so in CD8+
than in CD4+ T cells) and
signaling via the kinases
MEK and ERK, Foxp1 was
found to maintain the quies-
cent status of mature naive
CD8+ T cells. Foxp1 and
Foxo1 have the ability to
bind to the same predicted
forkhead-binding site in the
Il7r enhancer region, which
suggests that these two tran-scription factors might compete for the
binding and antagonize each other to
regulate IL-7 receptor a (IL-7Ra) expres-
sion in T cells (Feng et al., 2011). Hence,
it would be interesting to know whether
T cell specific overexpression of Foxo1
might phenocopy the effects of Foxp1
deletion with respect to anticancer im-
mune responses.
Is TGF-b the sole factor to upregulate
Foxp1 expression in the tumor microenvi-
ronment? Compared to quiescent periph-
eral T cells, intratumoral CD8+ T cells ex-
pressed higher amounts of the Foxp1a
isoform (or of the human ortholog
FOXP1.1). In addition to TGF-b, ICAM1
and Cxcl12 could reproducibly upregu-
late Foxp1a in recently primed tumor-
specific CD8+ T cells. In contrast, multiple
other potentially immunosuppressive fac-
tors were unable to induce Foxp1a. This
applies to myeloid suppressor cells, in-
flammatory cytokines (such as IL-1b,
IL-6, IL-17, IL-23, CCL3, PGE2, VEGFa),
interleukins involved in T cell homeostasis
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Previews(such as IL-2, IL-7, IL-15), Th2 cell-asso-
ciated cytokines, hypoxia, and estradiol
(Stephen et al., 2014). Altogether, these
findings underscore the relative ‘‘speci-
ficity’’ of the TGF-b-Foxp1 pathway.
The present work might have important
clinical implications. Inhibition of TGF-b
and its signaling pathway with antibodies
or antisense oligonucleotides or anti-
sense molecules targeting TGF-bRI or
RII is one possible strategy for boosting
anticancer immune responses. Adoptive
transfer of cytotoxic T lymphocytes engi-
neered to express a dominant-negative
mutant of the TGF-b receptor is also in
early development. As an alternative, the
emerging, ever-more practical genome-
editing technologies (such as transcrip-
tion-like effector nucleases and clustered
regularly interspaced short palindromicrepeats) might be used to engineer
T cells without TGF-b receptor subunits
or downstream effectors including
FOXP1 (Figure 1). Finally, the facts that
FOXP1 must cooperate with other tran-
scription factors including SMAD2 and
SMAD3 and simultaneously must antago-
nize FOXO1 might be taken advantage of
to create small molecules that disrupt
specific protein-protein or protein-DNA
interactions with the scope of creating a
new category of checkpoint blockers.REFERENCES
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The hallmark of bubonic plague is the presence of grotesquely swollen lymph nodes, called buboes.
This frenzied inflammatory response to Yersinia pestis is poorly understood. In this issue of Immunity,
St. John et al. (2014) explore the mechanism by which Y. pestis spreads and thus leads to this striking lymph-
adenopathy.In anticipation of microbial infections, the
dendritic cell (DC) acts as an early immune
detection system in tissue sites. Upon
encounter with a microbe, DCs quickly
mature and traffic to local draining lymph
nodes (dLNs), where they interact with
T cells and B cells to promote the devel-
opment of adaptive immunity. Simulta-
neously, neutrophils, monocytes, macro-
phages, and additional phagocytic cells
infiltrate tissues and attempt to eliminate
the microorganism before the adaptive
response is fully engaged. After clonal
expansion in LNs, lymphocytes also traffic
to sites of infection to combat pathogens.
Receptors and signaling molecules are
involved at every step along this processwith the goal of orchestrating an effective
immune response by multiple immune
cells.
These layers of protection appear
ideally suited to stop pathogens in their
tracks, but could the migration of cells
involved in immune defense collaborate
with the pathogen to support the progress
of disease? Certainly it appears that way
with HIV, in which DCs carrying intact vi-
rus traffic to LNs to deliver the microbe
to a site rich in susceptible host cells.
Bacterial pathogens that preferentially
replicate within lymphoid tissue, such as
Salmonella and Yersinia species, could
also follow this model, but the cellular ba-
sis for their migration into these tissues ispoorly understood (Viboud and Bliska,
2005; Zhang et al., 2008a; Zhang et al.,
2008b). In this issue of Immunity, St.
John et al. (2014) show that DCs play an
important role in delivering Yersinia pestis
into regional LNs, whereas other pha-
gocytic cells promote inter-LN spread
and thus support disease progression of
Y. pestis.
The terrifying bubonic plague, respon-
sible for the elimination of large portions
of the European population during epi-
demic outbreaks, is a consequence of
Y. pestis inoculation by infected fleas. An
impressive sign of disease is the bubo,
which is the result of an apparent unre-
strained swelling of LNs proximal to theptember 18, 2014 ª2014 Elsevier Inc. 347
